



January 2015

Adamis Pharmaceuticals to Penetrate Multi-Billion Dollar Allergy and Respiratory Markets with High Quality, Low Cost Therapeutic Alternatives


By Paul Silver

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a San Diego-based specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. Its specialty pharmaceuticals division, which currently has four products in its pipeline, is creating low-cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings for these products in order to minimize costs and shorten the time to market. The Company also has a four-product biotechnology pipeline that it is currently considering all of its options for how to strategically partner the assets. Therefore, the biotech division should be viewed as a free call option that could add value to shareholders.

Epinephrine Pre-Filled Syringe — Addressable Market \$900 M

The Epinephrine Pre-Filled Syringe (PFS) will compete as a simple, intuitive, low-cost therapeutic alternative to epinephrine auto injectors like Mylan's EpiPen® in the anaphylaxis market. In the U.S., an estimated 5% of the population suffers from insect sting anaphylaxis, up to 6% are latex sensitive and up to 1.5% of adults and 5% of children under three years of age experience food related anaphylaxis. Prescriptions have grown annually as the risk of anaphylaxis has been more widely understood. Estimated sales for Mylan's EpiPen® for 2013 was over \$800 million and growing ~15% annually. ADMP expects FDA

approval and commercial launch during the first half of 2015 at a significant price discount to its peers.



HFA Branded Generic Inhaled Oral Steroid — Addressable Market \$2.7 B

APC-1000 is a branded generic inhaled oral steroid for the treatment of asthma and COPD. For APC-1000, Adamis is using a well-known steroid (beclomethasone) and combining it with a HFA propellant to create a pulmonary metered dose inhaler (pMDI) with global potential. The Company believes that clinical and regulatory risks for this product are low, since this steroid has been well accepted and the clinical trial path to approval is well known. Adamis' manufacturer, Beximco, has demonstrated the know-how and ability to manufacture complex HFA products-overcoming the barriers to entry that have made it difficult for other firms to develop such products. Beximco currently manufactures and sells an APC-1000 like product for developing countries. ADMP intends to

begin a PK study in the 4Q of 2014 and a Phase III study in the first half of 2015. The Company anticipates FDA approval followed by the commercial launch during 2016.

HFA Branded Generic Inhaled Nasal Steroid — Addressable Market \$2.0 B

APC-3000 is a HFA branded generic inhaled nasal steroid for the treatment of seasonal and perennial allergic rhinitis. With the discontinuation of CFCs as propellants, this market has moved from gas propelled steroids to aqueous pumped steroids. However, many patients have difficulty using the aqueous delivered products, and the Company believes that there is an important unmet need to offer again the once dominant gas propelled inhaled nasal steroids. Adamis' strategy is to target that market segment by using a steroid that is well-known by both the FDA and the doctors who are doing the prescribing. This strategy helps to reduce the regulatory risk, since the company uses a well-known steroid that is off patent and couples it with an environmentally friendly HFA (a gas that has been cleared by the FDA). ADMP intends to begin a Phase III study in the second half of 2015 and expects a commercial launch in 2016/2017.

Branded Generic Dry Powder Inhaler — Addressable Market \$8.2 B worldwide

APC-5000 is Adamis' first product using the Taper Dry Powder Inhalation (DPI) technology that the Company has acquired from 3M Drug Delivery Systems. The Taper DPI is a patented pre-metered device that Adamis expects will have a number of advantageous features when compared to competing DPI products including: greater efficiency, less dependence on the individual's inspiratory flow rate, no need for excipients in most formulations, capability of delivering up to 120 doses (a two month supply), moisture protection, and ease of use. In addition, the device has been designed to reduce the likelihood of delivering a double dose. ADMP intends to initiate a proof-of-concept study comparing its APC-5000 with GSK's Advair in the second half of 2014 and expects a commercial launch in 2017. This platform technology can provide several follow-on products that can drive revenues for the foreseeable future.

Investment Conclusions

Adamis has four product launches anticipated between 2015 and 2017 in the multi-billion dollar allergy and respiratory markets. Given its product's competitive advantages, including being lower cost alternatives to existing products coupled with increased price sensitivity of consumers, the Company should be able to penetrate a meaningful percentage of these large and growing markets. As such, it represents a compelling investment for investors at these levels as well as an attractive M&A target by any of the major pharmaceutical companies.

Paul Silver




Paul Silver is the Managing Director of Research at Wall Street Resources. Previously he has been in auditing with a Big Four accounting firm in New York City, a sell-side research analyst for two global investment banks in New York City including Salomon Smith Barney and UBS Paine Webber. At Salomon Smith Barney he was a member of the firm's research team covering Real Estate Investment Trusts that was consistently ranked #1 by Institutional Investor magazine. Mr. Silver has written extensively on small cap equities and is a contributing writer to numerous publications is a co-manager of the WSR High Alpha model portfolio which has resulted in a 127.39% average annualized return from inception on March 13, 2009 through December 31, 2013. For more information visit:

<http://www.wallstreetresources.net/High Alpha Performance.aspx>

Performance Update 3-13-2009 through 12-31-2014

As we close the record books for 2014, we are very pleased to report the following results.



Portfolio or Index	Value 3/13/2009	Projected Value 12/31/2009	Projected Value 12/31/2010	Projected Value 12/31/2011	Projected Value 12/31/2012	Projected Value 12/31/2013	Projected Value 12/31/2014	Average Annualized Return
High Alpha Portfolio	\$10,000	\$19,541	\$42,767	\$93,600	\$204,851	\$448,333	\$981,214	118.86%
Dow Jones Industrial Average	\$10,000	\$11,363	\$13,293	\$15,550	\$18,191	\$21,280	\$24,894	16.98%
S&P 500	\$10,000	\$11,524	\$13,711	\$16,313	\$19,409	\$23,092	\$27,475	18.98%
NASDAQ	\$10,000	\$11,844	\$14,564	\$17,909	\$22,022	\$27,079	\$33,299	22.97%

Additional Portfolio Statistics:

High Alpha Portfolio 3/13/2009 to 12/31/2014	Open Positions	%	Closed Positions	%	Open & Closed Positions	%
Winning Trades	11/21	52%	77/99	78%	88/120	73%
Losing Trades	10/21	48%	22/99	22%	32/120	27%
Average Return	83.66%		61.05%		64.97%	
Average Annualized Return	-5.06%		144.88%		118.86%	

For a complete list of every trading alert from 3/13/2009 through 12/31/2014, as well as full access to all of our premium content, sign up for your risk free trial to WSR's High Alpha Stocks at:

https://www.wallstreetresources.net/HighAlpha_Signup.aspx

WSR's Featured Companies:

Wall Street Resources is a professional research and consulting firm connecting under-followed emerging growth companies with sophisticated investors looking for emerging growth company investment ideas. Leveraging over a decade of experience analyzing micro-to-small capital companies, the principals of WSR are dedicated to providing aggressive investors with unique opportunities, while helping emerging growth companies communicate with the investment community. The following companies are WSR's current clients which support its financial publications:

Featured Companies:**Adamis Pharmaceuticals , Inc.**
NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company's portfolio also includes two approved products developed with Forest. The first is a fixed-dose combination product, Namzaric, and the second is a controlled-release product, Namenda XR. Forest markets both products in the United States under an exclusive license from Adamas.

To obtain additional information go to: <http://www.wallstreetresources.net/Adamis.aspx>

Arch Therapeutics, Inc.
OTCQB:ARTH

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device(TM), is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

To obtain additional information go to: <http://www.wallstreetresources.net/Arch.aspx>

GeoVax Labs, Inc.
OTCQB:GOVX

GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax's unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. GeoVax's vaccines are currently being tested in human clinical trials, for both preventive and therapeutic applications. Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the U.S. National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious

Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in close to 500 humans.

To obtain additional information go to: <http://www.wallstreetresources.net/Geovax.aspx>

Highpower International, Inc.
NASDAQ:HPJ



Highpower International was founded in 2001 and produces high-quality Nickel-Metal Hydride (Ni-MH) and lithium-based rechargeable batteries used in a wide range of applications such as electric buses, bikes, energy storage systems, power tools, medical equipment, digital and electronic devices, personal care products, and lighting, etc. Highpower's target customers are Fortune 500 companies, and top 10 companies in each vertical segment. With advanced manufacturing facilities located in Shenzhen, Huizhou, and Ganzhou of China, Highpower is committed to clean technology, not only in the products it makes, but also in the processes of production. The majority of Highpower International's products are distributed to worldwide markets mainly in the United States, Europe, China and Southeast Asia.

To obtain additional information go to: <http://www.wallstreetresources.net/Highpower.aspx>

Inovio Pharmaceuticals, Inc.
NASDAQ:INO



Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.

To obtain additional information go to: <http://www.wallstreetresources.net/Inovio.aspx>

Liberator Medical Holdings, Inc.
OTCBB:LBMH



Liberator Medical Holdings, Inc.'s subsidiary, Liberator Medical Supply, Inc., established the Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to Medicare-eligible seniors. An Exemplary Provider(TM) accredited by The Compliance Team, its unique combination of marketing, industry expertise and customer service has demonstrated success over a broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience of direct billing to Medicare and private insurance. Approximately 85% of its revenue comes from supplying products to meet the rapidly growing requirements of general medical supplies, personal mobility aids, diabetes, urological, ostomy and mastectomy patients. Liberator communicates with patients and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.

To obtain additional information go to: <http://www.wallstreetresources.net/Liberator.aspx>

Midwest Energy Emissions Corp.
OTCQB:MEEC



Midwest Energy Emissions Corp. develops and employs patented and proprietary technologies to remove mercury from coal-fired power plant emissions. The U.S. Environmental Protection

Agency's (EPA) Mercury and Air Toxic Standards (MATS) rule requires that all coal- and oil-fired power plants in the U.S., larger than 25 mega-watts, must remove roughly 90% of mercury from their emissions starting April 16, 2015. Midwest employs patented technology that has been shown to achieve mercury removal levels compliant with MATS at a significantly lower cost and with less operational impact than currently used methods, while preserving the marketability of fly-ash for beneficial use, a roughly \$450mm industry annually. Management estimates that mercury emissions control is a recurring \$2-\$3 billion opportunity in the U.S. annually, with further international growth expected as countries adopt mercury emissions regulations under the United Nations Minimata Convention on Mercury.

To obtain additional information go to: <http://www.wallstreetresources.net/MidwestEnergy.aspx>

Sanomedics International Holdings, Inc.

OTCQB:SIMH



Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas "a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services. SIMH operates three wholly-owned subsidiaries: Thermomedics, Biscayne Medical and SanoER.

To obtain additional information go to: <http://www.wallstreetresources.net/Sanomedics.aspx>

OncoSec Medical, Inc.

OTCQB:ONCS



OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

To obtain additional information go to: <http://www.wallstreetresources.net/OncoSec.aspx>

Pulse Beverage Corporation

OTCQB:PLSB



Pulse Beverage Corporation is an emerging beverage company that offers a line of great tasting, refreshing, low-calorie natural drinks, including Natural Cabana Lemonade and Limeade, Natural Cabana Coconut Water and Pineapple Coconut Water, and PULSE brand of functional beverages. Combining all-natural ingredients, essential vitamins and minerals, Pulse's line of beverages provides consumers with high-quality, healthy alternatives at a reasonable price.

To obtain additional information go to: <http://www.wallstreetresources.net/PulseBeverage.aspx>

Sanomedics International Holdings, Inc.
OTCQB:SIMH



Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas "a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services. SIMH operates three wholly-owned subsidiaries: Thermomedics, Biscayne Medical and SanoER.

To obtain additional information go to: <http://www.wallstreetresources.net/Sanomedics.aspx>

Small Business Development Group, Inc.
OTC:SBDG



Small Business Development Group, Inc. (symbol: SBDG) is a current-information Pink company, incorporated in the State of Texas, trading on OTCMarkets.com, structured and operated as a holding company. It was formed in 2013 as a result of the rehabilitation and restructuring of a Virogen, Inc. Its purpose is four-fold: to acquire stable, profitable companies for its portfolio; through its subsidiaries, to provide a range of business and financial services to its portfolio companies, and to other entities, as a profit center; to serve as a test bed for the development and refinement of the premier SBDG business model, 'the Engineering of a Public Company'; and finally, to provide a vehicle for the spinoff of its mature portfolio silos into Business Development Companies (BDCs), or a stand-alone public or private company thereby creating structured exit strategies and liquidity events for owners and investors.

To obtain additional information go to: <http://www.sbdgp.com>

Stevia First Corporation
OTCQB:STF+VF



Stevia First Corp. is an agricultural biotechnology company that has developed expertise for the production of stevia using fermentation and for improvement of traditional stevia farming and processing methods. The Company is also applying breakthrough technologies in software and the life sciences to develop product applications far beyond stevia and the food and beverage industry.

To obtain additional information go to: <http://www.wallstreetresources.net/Sanomedics.aspx>

Vycor Medical, Inc.
OTCQB:VYCO



The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue. Vycor Medical's ViewSite Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injuries. To obtain additional information go to: <http://www.vycormedical.com>

Water Technologies Intl., Inc.
OTC:WTII

Water Technologies International, Inc., (WTII) is in the business of designing, manufacturing and distributing Atmospheric Water Generators (AWGs) and related products through its subsidiaries Aqua Pure International, Inc. and GR8 Water, Inc. The Company has patent pending products in water generation, air filtration, water filtration and dehumidification. WTII sells and distributes home, office and commercial AWGs units that produce drinking water, ranging from seven gallons to several thousands of gallons per day by extracting water from the air.

To obtain additional information go to: http://www.wallstreetresources.net/Water_Tech.aspx

DISCLAIMER - Wall Street Resources is an emerging growth company specialist, which publishes financial reports with respect to some of the securities that it covers and provides a newsletter and daily notes focused on micro-to-small capital companies on a subscription basis. The information contained in these publications is based upon sources, which we believe to be reliable, but is in no way warranted by us as to accuracy or completeness. The information contained herein is subject to change without notice, and we assume no responsibility to update the information in our financial publications. We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications or included in our newsletters. An employee, author, officer, or a director of the firm, or its affiliates, may serve as a director for companies mentioned in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned on this web site.

Past performance does not guarantee future success, and an investment in the model theoretical portfolio might lose money. Dividends and commissions are not included in performance calculations. The model theoretical performance includes performance history of the model micro-capital portfolio. The theoretical performance contains many high-risk speculative stocks, which tend to be more volatile and more illiquid than larger more established companies. The theoretical performance of the model does not represent actual trading and does not reflect material economic, psychological and market factors that might have impacted the results if actual money had been invested.

While no companies pay a fee to be included in our micro-capital portfolio or newsletter, certain companies, which are published as featured companies on our website, pay a due diligence fee for participation in the Wall Street Resources' financial publication and distribution program. In compliance with Section 17(b) of the Securities Act of 1933, detailed information regarding compensation from such companies is included on the last page of such reports, is explained in the disclaimer located at <http://wallstreetresources.net/disclaimer.html>, and is listed below. Tax consequences must be carefully considered. Wall Street Resources, Inc. is a financial publisher and not a broker/dealer or registered investment advisor, and thus all trades and actual trading decisions are made solely by the individual investor, not by Wall Street Resources, Inc. Wall Street Resources, Inc. and/or the employees of Wall Street Resources, Inc. will not be held responsible for any losses that might occur from the use of the information provided in our financial publications that might be acted upon by an investor. Changes in our theoretical portfolio and current quote prices are made as of the last trading day of each month and based upon the closed price.

Liberator Medical Holdings, Inc. - Wall Street Resources receives \$2,500 per month for investor relations services from Liberator Medical Holdings, Inc.

Water Technologies Intl., Inc. - Wall Street Resources received 1,500,000 shares of restricted common stock for research coverage and investor relations services from Water Technologies Intl., Inc. from June of 2011 until February of 2014.

Midwest Energy Emissions Corp. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Sanomedics International Holdings, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Arch Therapeutics, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

GeoVax Labs, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Highpower Internatinal, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Inovio Pharmaceuticals, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Stevia First Corporation - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Pulse Beverage Corporation - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

OncoSec Medical, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Small Business Development Group, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Vycor Medical, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Wall Street Resources, Inc. is not a broker/dealer or registered investment advisor and thus the information on this site is not intended to provide tax, legal or investment advice. The information does not constitute a solicitation of any order to buy or sell any securities. Wall Street Resources, Inc. is a financial publisher and not a broker/dealer or registered investment advisor, and thus all trades and actual trading, decisions are made solely by the individual investor, not by Wall Street Resources, Inc. Wall Street Resources, Inc. and/or the employees of Wall Street Resources, Inc. will not be held responsible for any losses that might occur from the use of the information provided by our newsletter services, or any other information related to Wall Street Resources, Inc. that might be acted upon by an investor. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Wall Street Resources, Inc.

This newsletter may contain forward-looking statements, particularly as related to pro forma financial statements, earnings estimates and business expectations, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. These forward-looking statements are only made as of the date of their release and Wall Street Resources and the companies discussed do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Wall Street Resources, Inc. is an information provider only. We cannot control market conditions, liquidity, market shutdowns, entry and exit prices, Internet shut-downs, or fax and mail delays. All investors should only invest or trade with capital that is risk capital that they can afford to lose. You may cancel your Wall Street Resources' newsletter service at any time and receive a full, pro-rata refund for the unused portion of your subscription. If emerging growth stock investing or trading seems too risky for you, you might want to consider starting with a less aggressive form of investing, such as the regular mutual fund contributions.

For additional information contact:

Wall Street Resources
3545 SW Corporate Parkway
Palm City, FL 34990
772-219-7525 (telephone)
www.wallstreetresources.net